ICCM (IceCure Medical, Ltd.) Return on Sales by Gross Profit

Changes in gross margin demonstrate the financial efficiency of IceCure Medical Ltd (ICCM). The value 34.70 reflects the latest metric reading. Growth is driven by the implementation of AI cryoablation systems that streamline physician workflows. Stable cash flows are supported by the expansion of the network of clinics purchasing consumables. The flawless brand image of ProSense in oncology solidifies the company's status as a leader in safe, non-surgical therapy of the future.
Comprehensive metric breakdowns and analytics for IceCure Medical, Ltd. (ICCM)

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of operational efficiency and the business's margin of safety. By analyzing gross margin dynamics, an investor can discern the ability of IceCure Medical Ltd (ICCM) to monetize its unique ProSense technology, where the brand's impeccable authority in oncology ensures a high pricing premium and revenue resilience against costs.